Digitally-enabled, Patient-centred Care in Rhinitis and Asthma Multimorbidity: The ARIA-MASK-air Approach

MASK-air , a validated mHealth app (Medical Device regulation Class IIa) has enabled large observational implementation studies in over 58,000 people with allergic rhinitis and/or asthma. It can help to address unmet patient needs in rhinitis and asthma care. MASK-air is a Good Practice of DG Santé on digitally-enabled, patient-centred care. It is also a candidate Good Practice of OECD (Organisation for Economic Co-operation and Development). MASK-air data has enabled novel phenotype discovery and characterisation, as well as novel insights into the management of allergic rhinitis. MASK-air data show that most rhinitis patients (i) are not adherent and do not follow guidelines, (ii) use as-needed treatment, (iii) do not take medication when they are well, (iv) increase their treatment based on symptoms and (v) do not use the recommended treatment. The data also show that control (symptoms, work productivity, educational performance) is not always improved by medications. A combined symptom-medication score (ARIA-EAACI-CSMS) has been validated for clinical practice and trials. The implications of the novel MASK-air results should lead to change management in rhinitis and asthma.

Citing Articles

Expert opinion on gray areas in asthma management: A lesson from the innovative project "revolution in asthma" of the Italian thoracic society (AIPO-ITS).

Vaghi A, Antonelli Incalzi R, Barbaglia S, Bilo M, Bini F, Carone M Clin Transl Allergy. 2025; 15(2):e70037.

PMID: 39924642 PMC: 11807766. DOI: 10.1002/clt2.70037.

The present and future of digital health, digital medicine, and digital therapeutics for allergic diseases.

Zhang H, Cao Y, Jiang H, Zhou Q, Yang Q, Cheng L Clin Transl Allergy. 2025; 15(1):e70020.

PMID: 39754327 PMC: 11702407. DOI: 10.1002/clt2.70020.

Medication adherence in allergic diseases and asthma: a literature review.

Malaya E, Piatkowska A, Panek M, Kuna P, Kupczyk M, Kardas G Front Pharmacol. 2024; 15:1488665.

PMID: 39687293 PMC: 11646763. DOI: 10.3389/fphar.2024.1488665.

The evolving reality of digital health.

Bit-Avragim N, Bousquet J, Cantu S, Omboni S, Ravot E, Tunnah P Digit Health. 2024; 10:20552076241277646.

PMID: 39347511 PMC: 11437555. DOI: 10.1177/20552076241277646.

Concurrent validity, cut-offs and ability to change of patient-reported outcome measures for rhinitis and asthma in MASK-air.

Bousquet J, Sousa-Pinto B, Anto J, Bedbrook A, Czarlewski W, Ansotegui I Clin Transl Allergy. 2024; 14(9):e12390.

PMID: 39313483 PMC: 11419846. DOI: 10.1002/clt2.12390.

References

Bousquet J, Schunemann H, Togias A, Bachert C, Erhola M, Hellings P . Next-generation Allergic Rhinitis and Its Impact on Asthma (ARIA) guidelines for allergic rhinitis based on Grading of Recommendations Assessment, Development and Evaluation (GRADE) and real-world evidence. J Allergy Clin Immunol. 2019; 145(1):70-80.e3. DOI: 10.1016/j.jaci.2019.06.049. View

Bousquet J, Dahl R, Khaltaev N . Global alliance against chronic respiratory diseases. Allergy. 2007; 62(3):216-23. DOI: 10.1111/j.1398-9995.2007.01307.x. View

Siroux V, Ballardini N, Soler M, Lupinek C, Boudier A, Pin I . The asthma-rhinitis multimorbidity is associated with IgE polysensitization in adolescents and adults. Allergy. 2018; 73(7):1447-1458. DOI: 10.1111/all.13410. View

Scadding G, Kariyawasam H, Scadding G, Mirakian R, Buckley R, Dixon T . BSACI guideline for the diagnosis and management of allergic and non-allergic rhinitis (Revised Edition 2017; First edition 2007). Clin Exp Allergy. 2018; 47(7):856-889. DOI: 10.1111/cea.12953. View

Courbis A, Murray R, Arnavielhe S, Caimmi D, Bedbrook A, Van Eerd M . Electronic Clinical Decision Support System for allergic rhinitis management: MASK e-CDSS. Clin Exp Allergy. 2018; 48(12):1640-1653. DOI: 10.1111/cea.13230. View

Bousquet J, Schroder-Bernhardi D, Bachert C, Canonica G, Cardona V, Costa E . Heterogeneity of the pharmacologic treatment of allergic rhinitis in Europe based on MIDAS and OTCims platforms. Clin Exp Allergy. 2021; 51(8):1033-1045. DOI: 10.1111/cea.13884. View

Azevedo P, Correia de Sousa J, Bousquet J, Bugalho-Almeida A, Del Giacco S, Demoly P . Control of Allergic Rhinitis and Asthma Test (CARAT): dissemination and applications in primary care. Prim Care Respir J. 2013; 22(1):112-6. PMC: 6442752. DOI: 10.4104/pcrj.2013.00012. View

Wiercioch W, Nieuwlaat R, Zhang Y, Alonso-Coello P, Dahm P, Iorio A . New methods facilitated the process of prioritizing questions and health outcomes in guideline development. J Clin Epidemiol. 2021; 143:91-104. DOI: 10.1016/j.jclinepi.2021.11.031. View

Bousquet J, Hellings P, Agache I, Amat F, Annesi-Maesano I, Ansotegui I . Allergic Rhinitis and its Impact on Asthma (ARIA) Phase 4 (2018): Change management in allergic rhinitis and asthma multimorbidity using mobile technology. J Allergy Clin Immunol. 2018; 143(3):864-879. DOI: 10.1016/j.jaci.2018.08.049. View

10.

Larenas-Linnemann D, Mullol J, Ivancevich J, Anto J, Cardona V, Dedeu T . [MASK (Mobile Airways Sentinel Network). ARIA's comprehensive solution for mobile app for the multimorbidity of allergic rhinitis and asthma]. Rev Alerg Mex. 2019; 66(1):140-146. DOI: 10.29262/ram.v66i1.578. View

11.

Bousquet J, Ansotegui I, Anto J, Arnavielhe S, Bachert C, Basagana X . Mobile Technology in Allergic Rhinitis: Evolution in Management or Revolution in Health and Care?. J Allergy Clin Immunol Pract. 2019; 7(8):2511-2523. DOI: 10.1016/j.jaip.2019.07.044. View

12.

Alonso-Coello P, Schunemann H, Moberg J, Brignardello-Petersen R, Akl E, Davoli M . GRADE Evidence to Decision (EtD) frameworks: a systematic and transparent approach to making well informed healthcare choices. 1: Introduction. BMJ. 2016; 353:i2016. DOI: 10.1136/bmj.i2016. View

13.

. 6. Glycemic Targets: . Diabetes Care. 2018; 42(Suppl 1):S61-S70. DOI: 10.2337/dc19-S006. View

14.

Scadding G . Optimal management of allergic rhinitis. Arch Dis Child. 2015; 100(6):576-82. PMC: 4514979. DOI: 10.1136/archdischild-2014-306300. View

15.

Piggott T, Brozek J, Nowak A, Dietl H, Dietl B, Saz-Parkinson Z . Using GRADE evidence to decision frameworks to choose from multiple interventions. J Clin Epidemiol. 2020; 130:117-124. DOI: 10.1016/j.jclinepi.2020.10.016. View

16.

Sousa-Pinto B, Anto J, Sheikh A, de Lusignan S, Haahtela T, Almeida Fonseca J . Comparison of epidemiologic surveillance and Google Trends data on asthma and allergic rhinitis in England. Allergy. 2021; 77(2):675-678. DOI: 10.1111/all.15139. View

17.

Bousquet J, Bedbrook A, Czarlewski W, Onorato G, Arnavielhe S, Laune D . Guidance to 2018 good practice: ARIA digitally-enabled, integrated, person-centred care for rhinitis and asthma. Clin Transl Allergy. 2019; 9:16. PMC: 6413444. DOI: 10.1186/s13601-019-0252-0. View

18.

Bousquet J, Schunemann H, Togias A, Erhola M, Hellings P, Zuberbier T . Next-generation ARIA care pathways for rhinitis and asthma: a model for multimorbid chronic diseases. Clin Transl Allergy. 2019; 9:44. PMC: 6734297. DOI: 10.1186/s13601-019-0279-2. View

19.

. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther. 2001; 69(3):89-95. DOI: 10.1067/mcp.2001.113989. View

20.

Bousquet J, Demoly P, Michel F . Specific immunotherapy in rhinitis and asthma. Ann Allergy Asthma Immunol. 2001; 87(1 Suppl 1):38-42. DOI: 10.1016/s1081-1206(10)62193-x. View